Inflammation

The assessment of bio-humoral markers beyond clinical evaluation would allow a more comprehensive pheno/endotyping of patients affected by chronic inflammatory diseases. Therapy personalization would require a profile of the mediators that are relevant in the disease pathogenesis and that well correlate with prognosis. Currently, the measurement of multiple biomarkers is not included in patient evaluation because it has high costs,  requires centralized laboratories, experienced personnel and bulky equipment and is time-consuming.

We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.